References
- Nickoloff B. J., Nestle F. O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664–75
- Godic A. New approaches to psoriasis treatment. A review. Acta Derm Venereol 2004; 13: 50–7
- Ellis C. N., Krueger G. G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248–55
- Kraan M. C., van Kuijk A. W. R., Dinant H. J., Goedkoop A. Y., Smeets T. J. M., de Rie M. A., et al. Alefacept treatment in psoriatic arthritis – Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002; 46: 2776–84
- Gottlieb A. B., Casale T. B., Frankel E., Goffe B., Lowe N., Ochs H. D., et al. CD4(+) T‐cell‐directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 2003; 49: 816–25
- Gordon K. B., Vaishnaw A. K., O'Gorman J., Haney J., Menter A. Treatment of psoriasis with alefacept – Correlation of clinical improvement with reductions of memory T‐cell counts. Arch Dermatol 2003; 139: 1563–70
- Lowe N. J., Gonzalez J., Bagel J., Caro I., Ellis C. N., Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003; 42: 224–30
- Krueger G. G., Callis K. P. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49: S87–S97
- Gottlieb A. B. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg 2004; 8: 14–19
- Lebwohl M., Christophers E., Langley R., Ortonne J. P., Roberts J., Griffiths C. E. M. An international, randomized, double‐blind, placebo‐controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719–27
- Ortonne J. P. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 12–16
- Van de Kerkhof P. C., Vissers W. H. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 2003; 16: 69–83
- Berth‐Jones J., Damstra R. J., Golsch S., Livden J. K., Van H. O., Allegra F., et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study. BMJ 2003; 326: 1367
- Duweb G., Aldebani S., Elzorghany A., Benghazil M., Alhaddar J. Calcipotriol ointment versus cream in psoriasis vulgaris. Int J Clin Pharmacol Res 2003; 23((2–3))47–51
- Roeder A., Schaller M., Schafer‐Korting M., Korting H. C. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol 2005; 18: 3–11
- Krueger G. G. Selective targeting of T cell subsets: Focus on alefacept – a remittive therapy for psoriasis. Expert Opin Biol Ther 2002; 2: 431–41